Core Laboratories Inc.
CLB
$10.44
-$0.16-1.51%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 517.38M | 517.80M | 523.85M | 522.82M | 513.77M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 517.38M | 517.80M | 523.85M | 522.82M | 513.77M |
| Cost of Revenue | 416.17M | 415.40M | 420.52M | 415.84M | 405.65M |
| Gross Profit | 101.20M | 102.39M | 103.33M | 106.98M | 108.12M |
| SG&A Expenses | 40.65M | 40.46M | 38.59M | 38.09M | 38.88M |
| Depreciation & Amortization | 14.73M | 14.83M | 14.95M | 15.16M | 15.42M |
| Other Operating Expenses | -2.16M | -2.90M | -2.32M | -2.47M | -1.57M |
| Total Operating Expenses | 469.40M | 467.79M | 471.75M | 466.63M | 458.38M |
| Operating Income | 47.98M | 50.01M | 52.10M | 56.20M | 55.39M |
| Income Before Tax | 42.64M | 42.85M | 46.19M | 45.61M | 40.44M |
| Income Tax Expenses | 12.42M | 14.12M | 14.03M | 18.49M | 16.10M |
| Earnings from Continuing Operations | 30.21 | 28.73 | 32.15 | 27.12 | 24.33 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -581.00K | -706.00K | -753.00K | -922.00K | -626.00K |
| Net Income | 29.63M | 28.03M | 31.40M | 26.20M | 23.71M |
| EBIT | 47.98M | 50.01M | 52.10M | 56.20M | 55.39M |
| EBITDA | 62.71M | 64.83M | 67.05M | 71.36M | 70.80M |
| EPS Basic | 0.63 | 0.59 | 0.67 | 0.56 | 0.51 |
| Normalized Basic EPS | 0.46 | 0.48 | 0.50 | 0.54 | 0.53 |
| EPS Diluted | 0.62 | 0.59 | 0.66 | 0.55 | 0.49 |
| Normalized Diluted EPS | 0.46 | 0.47 | 0.49 | 0.53 | 0.52 |
| Average Basic Shares Outstanding | 188.10M | 188.38M | 188.46M | 188.25M | 188.02M |
| Average Diluted Shares Outstanding | 189.73M | 190.11M | 191.04M | 190.82M | 190.61M |
| Dividend Per Share | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Payout Ratio | 6.33% | 6.70% | 5.97% | 7.15% | 7.90% |